

dermagold100®



With dermagold100[®], MTS launches a multitalented premium device. Progressive operating technology, exclusive design and the latest MTS Spark Wave[®] technology guarantee shockwave therapy at it's best.

Touch screen and touch wheel ensure easy appliance and progressive operating technology for daily use. The modern and compact design particularly qualifies dermagold100[®] for portable use.

High-quality materials and the latest MTS technology guarantee most consistent Spark Waves[®] for optimal treatment quality.





The effectiveness of ESWT is fully proven for numerous indications. Recent research has shown that shock waves have highly beneficial effects on skin lesions. It is proven that tissue which is exposed to shock waves initiates the production of VEGF (vessel endothelial growth factor), which in turn activates the growth of new blood vessels. In addition, it has also been established that shock waves produce an antibacterial effect. The combination of these two effects initiates a healing process in skin lesions and stimulates the development of new tissue.

dermagold100[®] represents the first therapy system which specifically utilizes the biological effects of Spark Waves[®]. With this device MTS opens up a new field of therapy for chronic wounds and skin lesions.

MTS patented Spark Wave® Technology offers the medically most effective shockwave treatment for

Indications approved for dermagold 100[®]

- Non-healing lesions
- Acute and chronic lesions
- Post traumatic lesions
- Post-operative healing disorders

Indications in clinical use

- Venous ulcers
- Arterial ulcers
- Decubitus ulcers
- Diabetic foot syndrome
- Burns





Tissue regeneration - unfocused applicator

The clinically tested unfocused applicator, an innovation of MTS, emits unique and mainly unfocused shock waves that are specially designed for skin indications. To achieve optimal treatment results the energy volume and energy arrangement were accommodated for the treatment of skin lesions.

Treatment without anaesthesia

The treatment does not require any anaesthesia because the large focal zone of the dermagold100[®] applicator significantly reduces the pain typically associated with shock wave treatment. The number of required treatments for each skin lesion varies, depending on the type of lesion and the wound surface.





Picture 1: Pressure ulcer in patient with paralysis of the forefoot after surgical intervention at spinal column Picture 2: Situation after shock wave treatment



dermagold100®

Technical Data

Applicator OP155 Therapeutic Focus fz (-6dB): Energy Flux Density (ED): Focus Energy (E total / -6dB):

Dimensions: Power Supply: Power Input: Repetition Rate: Weight: 0 – 82 mm 0.01 – 0.19 mJ/mm² 0.40 – 3.88 mJ

21.8 x 40 x 45.9 cm AC 100 - 240 V, 50 - 60 Hz 200 VA 0.5 - 8 Hz 16.5 kg

MTS is specialized in development, manufacture and distribution of Spark Wave® therapy systems that are successfully used worldwide in orthopedics, traumatology, wound care and urology. Our patented Spark Wave® technology guarantees the medically most effective shock waves, a consistently high treatment quality as well as excellent treatment results that are achieved with the lowest number of treatments required of all technologies.

For the development of innovative therapy methods – even for indications which are mard to treat – we cooperate with internationally renowned universities and research institutions and are able to offer not only numerous clinical evidence studies but also a leading position in different international markets. We therefore consider ourselves among the pioneers in the field of non-invasive tissue healing and regeneration. Let yourself be convinced by the Spark of Evidence.

MTS Medical UG Robert-Bosch-Str. 18 78467 Konstanz, Germany Tel +49 (0) 7531 36185-0 Fax +49 (0) 7531 36185-70 info@mts-medical.com www.mts-medical.com

